US Stock IR Daily – July 06, 2026 (4 reports)

• Duke Energy Carolinas, LLC (DEC) reached a partial settlement (the “Stipulation”) with the Public Staff – North Carolina Utilities Commission regarding DEC’s application for adjustment of rates and charges and for Performance Based Regulation (PBR), filed with the North Carolina Utilities Commission (NCUC) on November 20, 2025.
• The Stipulation includes agreement on certain operating and maintenance costs, project-specific capital expenditures, rider mechanisms, and accounting adjustments.
• The Stipulation does not include an agreement on return on equity, capital structure, certain capital investments including the overall Multi-Year Rate Plan capital program, depreciation and decommissioning, storm-related cost recovery, or performance incentive mechanisms, among other items.
• The Stipulation will result in a one-time pre-tax accounting charge of approximately $10 million, to be recognized in the second quarter of 2026.
• Testimony consistent with the Stipulation is scheduled to be filed next week.

Duke Energy Carolinas reaching a partial settlement on its rate adjustment application may suggest progress in resolving certain regulatory uncertainties related to operating costs and specific capital expenditures. However, key financial aspects such as return on equity and capital structure remain unresolved, indicating further negotiations are likely. The disclosed one-time accounting charge of approximately $10 million for Q2 2026 is a specific financial impact for investors to monitor.

• Regeneron Pharmaceuticals, Inc. expects its financial results for the second quarter of 2026 to include an acquired in-process research and development (IPR&D) charge of approximately $127 million on a pre-tax basis.
• This charge is related to up-front and opt-in payments in connection with collaboration and licensing agreements.
• The acquired IPR&D charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share for the second quarter of 2026 by approximately $1.00.
• Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of their future occurrence, magnitude, and timing in any given period.
• The company’s results for the second quarter of 2026 have not been finalized and are subject to its financial statement closing procedures, and the estimates described are preliminary (unaudited).

Regeneron Pharmaceuticals’ announcement indicates an expected pre-tax acquired IPR&D charge of approximately $127 million for Q2 2026, which is anticipated to impact diluted EPS by about $1.00. This charge, linked to collaboration and licensing agreements, may suggest the company’s ongoing investment in strengthening its pipeline through external partnerships. The company’s stance on not forecasting such charges could reflect the inherent unpredictability of deal timing in the pharmaceutical industry.

• S&P Global Inc. filed an Amendment No. 1 to its Current Report on Form 8-K, originally filed on July 1, 2026.
• This amendment reflects the previously announced separation (spin-off) of Mobility Global Inc. (“Mobility Global”) from S&P Global, which became effective on July 1, 2026.
• The separation was achieved through S&P Global’s distribution of 100% of Mobility Global common stock to S&P Global common stockholders, with each stockholder receiving one share of Mobility Global common stock for every share of S&P Global common stock held as of the Record Date (June 15, 2026).
• Following the Distribution, Mobility Global became an independent public company, with its common stock listed under the symbol “MBGL” on the New York Stock Exchange.
• The Amendment No. 1 includes unaudited pro forma financial information of S&P Global, reflecting the performance of S&P Global’s business after giving effect to the Separation, attached as Exhibit 99.2.
• On July 6, 2026, S&P Global issued a press release (Exhibit 99.1) providing financial information for full year 2025, the four quarters of 2025, and the first quarter of 2026, updated to reflect the completion of the Mobility Global spin-off and segment recast.

S&P Global’s filing of Form 8-K/A indicates the official completion of the Mobility Global spin-off and the integration of its effects into the company’s financial reporting. This provides investors with updated pro forma financial statements, which may offer a clearer picture of S&P Global’s post-separation business structure and financial standing. The updated historical financial data, presented in the context of the spin-off and segment reclassification, could be crucial for analyzing future business performance.

• Broadcom Inc. and Apple Inc. have agreed to expand their long-standing technology collaboration through 2031.
• This expansion includes new multi-year long-term agreements for Broadcom to develop and supply a range of custom ASIC (Application-Specific Integrated Circuit) silicon products.
• These custom ASIC silicon products are intended for use in multiple generations of Apple products.
• The information was reported via a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC) on July 6, 2026.

Broadcom’s announcement of an expanded long-term partnership with Apple through 2031 suggests a continuation of a significant revenue stream from a key customer. The agreement to develop and supply custom ASIC silicon for multiple generations of Apple products could indicate a sustained demand for Broadcom’s specialized semiconductor solutions. This extended commitment may provide a degree of long-term revenue visibility and stability for Broadcom’s semiconductor segment.